
Rheumatoid arthritis Program in Pharmaceutical Benefits Scheme (PBS) 012-18051134

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised biological agents for
patients with rheumatoid arthritis (RA).

Rheumatoid arthritis and listing dates

Rheumatoid arthritis (RA) is a form of arthritis that causes pain,
swelling and loss of joint function.

Listing dates are:

-   etanercept - 1 August 2003
-   infliximab - 1 February 2004
-   adalimumab - 1 May 2004
-   abatacept - 1 March 2008
-   certolizumab- 1 August 2010
-   golimumab- 1 August 2010
-   tocilizumab- 1 August 2010
-   tofacitinib - 1 October 2015
-   baricitinib - 1 September 2018
-   upadacitinib - 1 May 2020

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, calculation
sheets, contact details, item and restriction codes, FAQs, the PBS
schedule and the Services Australia websites.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing written authority approval requests

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
